Trials / Suspended
SuspendedNCT06235281
Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)
A Single-Arm, Open-Label, Pilot Study of Concurrent Phototherapy and POTELIGEO (Mogamulizumab-kpkc) in Early Stage Mycosis Fungoides (PLIGHT)
- Status
- Suspended
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, single arm, single-center, pilot study of concurrent phototherapy and POTELIGEO (mogamulizumab-kpkc) in early-stage mycosis fungoides.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mogamulizumab-Kpkc | Participants will receive 8 total cycles of Mogamulizumab-Kpkc over approximately 224 days. |
| DEVICE | Phototherapy | Participants will begin receiving Phototherapy on day 56 and will continue until day 224. Participants with Complete response (CR) or Partial response (PR) to therapy at day 224 will remain on phototherapy maintenance. |
Timeline
- Start date
- 2024-01-18
- Primary completion
- 2026-09-01
- Completion
- 2029-09-01
- First posted
- 2024-01-31
- Last updated
- 2026-02-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT06235281. Inclusion in this directory is not an endorsement.